Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

被引：32
|
作者：
Speer, Michael E. [1 ]
Fernandes, Caraciolo J. [1 ]
Boron, Marnie [2 ]
Groothuis, Jessie R. [2 ]
机构：
[1] Baylor Coll Med, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA
[2] Medimmune Inc, Gaithersburg, MD 20878 USA
来源：
PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2008年 / 27卷 / 06期
关键词：
cystic fibrosis; RSV; palivizumab; hospitalization;
D O I：
10.1097/INF.0b013e3181673c15
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The Palivizumab Outcomes Registry collected data on 19,548 high-risk infants who received >= 1 dose of palivizumab and followed prospectively from 2000 through 2004. Ninety-one children with cystic fibrosis (CF) were identified who received palivizumab off label. None of the infants with CF who received prophylaxis was hospitalized as a result of respiratory syncytial virus lower respiratory tract infection. Evaluations of palivizumab use in infants with CF could be warranted.
引用
收藏
页码：559 / 561
页数：3
相关论文
共 50 条
  • [21] Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants
    Banerji, Anna
    Lanctot, Krista L.
    Paes, Bosco A.
    Masoud, Shababa T.
    Tam, Derrick Y.
    Macdonald, W. Alexander
    Roberts, Ann
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (08) : 702 - 706
  • [22] Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
    Brady, Michael T.
    Byington, Carrie L.
    Davies, H. Dele
    Edwards, Kathryn M.
    Jackson, Mary Anne
    Maldonado, Yvonne A.
    Murray, Dennis L.
    Orenstein, Walter A.
    Rathore, Mobeen H.
    Sawyer, Mark H.
    Schutze, Gordon E.
    Willoughby, Rodney E.
    Zaoutis, Theoklis E.
    Ralston, Shawn L.
    Lieberthal, Allan S.
    Meissner, H. Cody
    Alverson, Brian K.
    Baley, Jill E.
    Gadomski, Anne M.
    Johnson, David W.
    Light, Michael J.
    Maraqa, Nizar F.
    Mendonca, Eneida A.
    Phelan, Kieran J.
    Zorc, Joseph J.
    Stanko-Lopp, Danette
    Hernandez-Cancio, Sinsi
    PEDIATRICS, 2014, 134 (02) : 415 - 420
  • [23] Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation
    Yeo, Kee Thai
    Yung, Chee Fu
    Khoo, Poh Choo
    Saffari, Seyed Ehsan
    Sng, Jane Swee Peng
    How, Mee See
    Quek, Bin Huey
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (02): : 279 - 287
  • [24] Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion
    Meissner, HC
    Welliver, RC
    Chartrand, SA
    Law, BJ
    Weisman, LE
    Dorkin, HL
    Rodriguez, WJ
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (03) : 223 - 231
  • [25] Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden
    Neovius, Kristian
    Buesch, Katharina
    Sandstrom, Kristina
    Neovius, Martin
    ACTA PAEDIATRICA, 2011, 100 (10) : 1306 - 1314
  • [26] The Prevention of Respiratory Syncytial Virus Infection in Children: Focus on Palivizumab
    Speer, Michael E.
    Good, Amy B.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 459 - 469
  • [27] Expert consensus on palivizumab use for respiratory syncytial virus in developed countries
    Sanchez Luna, Manuel
    Manzoni, Paolo
    Paes, Bosco
    Baraldi, Eugenio
    Cossey, Veerle
    Kugelman, Amir
    Chawla, Rupesh
    Dotta, Andrea
    Rodriguez Fernandez, Rosa
    Resch, Bernhard
    Carbonell-Estrany, Xavier
    PAEDIATRIC RESPIRATORY REVIEWS, 2020, 33 : 35 - 44
  • [28] Palivizumab - the humanised monoclonal antibody for prevention of respiratory syncytial virus (RSV) infection
    Scholz, H
    ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2000, 204 (03): : 120 - 122
  • [29] Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab
    Paes, Bosco
    Mitchell, Ian
    Yi, Hao
    Li, Abby
    Lanctot, Krista L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (02) : E29 - E33
  • [30] Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab
    Resch, Bernhard
    Michel-Behnke, Ina
    CURRENT OPINION IN CARDIOLOGY, 2013, 28 (02) : 85 - 91
12345